I-Cannabidiol (CBD)

I-Cannabidiol (I-CBD) impuphu Ulwazi oluyisisekelo

Igama	ICannabidiol （CBD）
ukubukeka	I-powder emhlophe ekhanyayo ephuzi
CAS	13956-29-1
yokuncwaninga izinsimbi kanye namakhemikhali	≥99% (HPLC)
solubility	Incibilika emafutheni, encibilika ngokweqile ku-ethanol ne-methanol, ayincibiliki emanzini
isisindo Yamamolekhula	314.46
Melt Point	I-62-63 ° C
Formula Yamamolekhula	C21H30O2
Umthombo	Izimboni hemp
Isitoreji Temp	Izinga lokushisa ekamelweni, hlala womile futhi ungakhanyisi
Grade	I-Pharmaceutical Grade

 

Kuyini I-Cannabidiol (I-CBD)?

I-Cannabidiol yaziwa njenge-CBD engenye yamakhemikhali angaphezu kwekhulu eyaziwa ngokuthi ama-cannabinoids atholakala esitshalweni se-cannabis noma insangu, iCannabis sativa. Ihlukanisiwe futhi ihlanzwe kusuka emithini ye-Cannabis sativa, iqukethe inani elincane kakhulu le-THC. I-Tetrahydrocannabinol (iTHC) ne-cannabidiol (i-CBD) zombili ziyasebenzisana nama-receptors we-cannabinoid emzimbeni wonke.Iqhathaniswa ne-100-THC, i-CBD ayinabuthi njengoba ingakhombisi ukusebenza kwengqondo. Inemisebenzi ye-analgesic, anti-inflammatory, antineoplastic and chemopreventive. Lapho sekuphethwe, i-cannabidiol (i-CBD) inesenzo sayo sokulwa nokwanda, i-anti-angiogenic kanye ne-pro-apoptotic ngokusebenzisa izindlela ezahlukahlukene, okungenzeka ukuthi azibandakanyi ukusayinwa kwe-cannabinoid receptor 9 (CB1), CB1, noma i-vanilloid receptor 2. I-CBD ivuselela i-endoplasmic ukucindezelwa kwe-reticulum (ER) futhi kuvimbela ukusayinwa kwe-AKT / mTOR, ngaleyo ndlela kusebenze i-autophagy nokukhuthaza i-apoptosis. Ngaphezu kwalokho, i-CBD ithuthukisa ukukhiqizwa kwezinhlobo zomoya-mpilo ezisebenzayo (i-ROS), okuqhubeka nokuthuthukisa i-apoptosis. Lo menzeli uphinde alungise ukubonakaliswa kwe-intercellular adhesion molecule 1 (ICAM-1) kanye ne-tissue inhibitor ye-matrix metalloproteinases-1 (TIMP1) futhi inciphise ukubonakaliswa kwe-inhibitor ye-DNA ebopha i-1 (ID-1). Lokhu kuvimbela ukungena komdlavuza weseli nomdlavuza. I-CBD ingase futhi isebenzise i-vanilloid type 1 (TRPV2) yesikhashana yokwamukela okungase kuthuthukise ukutholwa kwama-cytotoxic agents kumaseli womdlavuza. Umphumela we-analgesic we-CBD ulamula ngokubopha kwalesi sisebenzisi nokwenza kusebenze kwe-CB2. I-Cannabidiol isetshenziswa kakhulu ekuphazamisekeni kokuquleka (isithuthwane) noma i-dravet syndrome nokukhululeka okuyisibonakaliso kokuqaqamba kobuhlungu besifo semizwa noma ezinye izimo ezibuhlungu, njengomdlavuza. I-FDA igunyaze i-CBD ngo-1, futhi ukuphela kwokwelapha okugunyaziwe kwe-FDA kweziguli ezine-Lennox-Gastaut syndrome kanye ne-Dravet syndrome.

 

Cumabhebhana (I-CBD) Inqubo yesenzo

Indlela eqondile yokusebenza kwe-CBD ne-THC okwamanje ayiqondakali ngokuphelele. Kodwa-ke, kuyaziwa ukuthi i-CBD isebenza kuma-receptors we-cannabinoid (CB) wohlelo lwe-endocannabinoid, atholakala ezindaweni eziningi zomzimba, kufaka phakathi amasistimu ezinto ezisemaphethelweni naphakathi, kubandakanya nobuchopho. Uhlelo lwe-endocannabinoid lulawula izimpendulo eziningi zomzimba zomzimba kufaka phakathi izinhlungu, inkumbulo, isifiso sokudla nemizwa. Ngokuqondile, ama-CB1 receptors angatholakala ngaphakathi kwezindlela ezibuhlungu zobuchopho nomgogodla lapho angathinta khona i-analgesia eyenziwe nge-CBD kanye ne-anxiolysis, futhi ama-receptors e-CB2 anomthelela kumaseli omzimba, lapho angathinta khona izinqubo zokulwa nokuvuvukala ezibangelwa yi-CBD . I-Cannabidiol (i-CBD) yi-metabolism eyenzeka esibindini nasemathunjini. Ukubhema ukutholakala kokutholakala cishe kungama-31%. Impilo yengxenye ye-CBD ngemuva kwe-oromucosal spray iphakathi kwamahora angu-1.4 no-10.9, izinsuku ezi-2 nezingu-5 ngemuva kokudla ngomlomo okungapheli, namahora angama-31 ngemuva kokubhema. I-CBD izofinyelela inani eliphakeme le-plasma phakathi kwamahora angu-0 no-4. I-CBD ikhonjiswe ukuthi isebenza njenge-moduli ye-allosteric engeyinhle ye-cannabinoid CB1 receptor, i-G-Protein Coupled Receptor (GPCR) egcwele kakhulu emzimbeni. Ukulawulwa kwe-Allosteric kwe-receptor kutholwa ngokushintshashintsha komsebenzi we-receptor esizeni esisebenza ngokuhlukile esizeni esibopha i-agonist noma i-antagonist. Imiphumela emibi ye-allosteric modulatory ye-CBD ibalulekile ekwelapheni njengoba ama-agonists aqondile enqunyelwe yimiphumela yawo yokusebenza kwengqondo ngenkathi abamelene ngqo benqunyelwe yimiphumela yabo ecindezelayo.

 

Ungayisebenzisa Kanjani uCumabhebhana (I-CBD)?

I-Cannabidiol (i-CBD) ingukukhishwa kwe-cannabis okwenzelwe izinzuzo zayo zezempilo. Izindlela ezimbili ezijwayelekile zokuyiyisa emakethe ezomlomo nezihloko, njengama-capsules, ama-tinctures, okhilimu, nokuningi. Amafutha e-CBD ayisitayela sokufaka isicelo esithandwa kakhulu, kuyindlela ephumelelayo yokwenza umthamo we-cannabinoid. Ukugwinya amaconsi amaningana kawoyela we-CBD kusebenza njengendlela elula nehleleke kakhulu yokusebenzisa i-molecule ngale ndlela. ICannabidiol INGABE IPHEPHELEKILE uma ithathwa ngomlomo noma ifuthwe ngaphansi kolimi ngokufanele. I-Cannabidiol ngemithamo efinyelela ku-300 mg nsuku zonke ithathwe ngomlomo ngokuphepha izinyanga ezi-6. Imithamo ephakeme ye-1200-1500 mg nsuku zonke ithathwe ngomlomo ngokuphepha kuze kube amasonto ama-4. Umkhiqizo kadokotela we-cannabidiol (i-Epidiolex) uvunyelwe ukuthi uthathwe ngomlomo ngemithamo efinyelela kuma-25 mg / kg nsuku zonke. Izifutho zeCannabidiol ezisetshenziswa ngaphansi kolimi zisetshenzisiwe ngemithamo ye-2.5 mg amasonto angafika kwamabili. Umuntu angangeza uwoyela we-CBD ekudleni nasekuphuzeni ukumboza ukunambitheka. Kepha kulabo abafuna ukusiza ngedolo elixegayo noma emuva okuqinile, kungakhethwa ukhilimu.

 

I-Cannabidiol (I-CBD) Zuza

I-Cannabidiol (i-CBD ngamafuphi) iyi-cannabinoid eyenzeka ngokwemvelo etholakala esitshalweni se-cannabis. Ingenye yama-cannabinoid angaphezu kwekhulu akhonjwe ezitshalweni ze-hemp. Kodwa-ke, ngokungafani nesitshalo se-cannabis esigcwele, i-CBD ayiqukethe i-THC ebhekele umuzwa okhandwe ngamatshe / ophakeme owunikezwa umuthi wokuzithokozisa. Kukhishwe ezimbalini naseziqhumeni zesitshalo se-hemp, i-CBD icindezelwa emafutheni futhi iya ngokuya ithandwa ukwelapha, nokuvikela, inqwaba yezinkinga zezempilo ezindaweni lapho insangu yezokwelapha isemthethweni khona manje. Uwoyela we-CBD unamandla futhi ungokwemvelo kunemithi eminingi engeyona eye-steroidal anti-inflammatory (NSAIDs). Zombili lezi zinto zingakhishwa futhi zithuthukiselwe ukusetshenziswa ngokusebenzisa i-distillation yendlela emfushane. Abasebenzisi bangathola izinzuzo zezempilo ezilandelayo:

* Ukungalali nokukhathazeka

* Izinkinga ze-Neurodegenerative

* Lawula ukuquleka

* .Izinkinga Zengqondo Nezinkinga Ezihlobene Nesimo

* Ikhwalithi Yokulala

* Ukuphathwa Kwezinhlungu

* Amathambo Ezempilo

* Umlutha Nokuncika

* Ukukhula kancane kwesifo i-Alzheimer's

* Welapha izifo ezivuthayo zamathumbu

* .Usizo lunikeza ukukhululeka kubantu abane-multiple sclerosis

 

I-Cannabidiol (I-CBD) Okuqhamuka uma udla imishanguzo

Imiphumela emibi ye-Cannabidiol (CBD) ifaka ukozela, izingqinamba zamathumbu, umlomo owomile, ukunciphisa ukudla, isicanucanu nokuxhumana neminye imithi.

I-Cannabidiol (I-CBDIsicelo

I-Cannabidiol isetshenziswa kakhulu ekuhlaselweni yisifo sokuwa (isithuthwane), i-Cannabinoid ihlanganiswa ne-cytochrome P450 enzyme system futhi ivimbele ikakhulu ama-enzyme CYP3A4 kanye ne-CYP2D6. I-THC ne-CBD kutholakale ukuthi zivimbela ama-enzyme e-CYP1A1, 1A2 kanye ne-1B1 ngesikhathi sezifundo ze-in vitro. Ngaphezu kwalokho i-CBD iyisithibeli esinamandla se-CYP2C1P ne-CYP3A4. Njengoba kuqhubeka ukuhlolwa okuningi kwemitholampilo, i-CBD ikhombisa amandla amangalisayo okuba ukwelashwa okwengeza ezimweni ezahlukahlukene zezinzwa. Kutholakale ukuthi inemiphumela yokulwa ne-antioxidative, anti-inflammatory, kanye ne-neuroprotective. Kukhombise isithembiso ekwelapheni ukuphazamiseka kwemithambo yegazi njengokukhathazeka, ubuhlungu obungapheli, i-trigeminal neuralgia, isifo seCrohn, isifo seParkinson kanye nokuphazamiseka kwengqondo.

I-Cannabidiol Isifinyezo

I-Cannabidiol iyi-cannabinoid etholakala ngomlomo esetshenziselwa ukwelapha iziguli ezinesifo sokuwa ngenxa yeLennox-Gastaut noma iDravet syndrome. I-Cannabidiol ihlotshaniswa nokuphakama kwe-enzyme ejwayelekile ngesikhathi sokwelapha ikakhulukazi ngemithamo ephakeme kepha ayixhunywanga emacaleni okulimala kwesibindi okwenzeka emtholampilo nge-jaundice.

 

Izikhombo

I-Britch SC, i-Babalonis S, i-Walsh SL, i-Cannabidiol: i-pharmacology nezinhloso zokwelashwa. I-Psychopharmacology (Berl). 1 Jan; 2021 (238): 1-9. i-doi: 28 / s10.1007-00213-020-05712. I-PMID: 8.

2. I-Samanta D. Cannabidiol: Ukubuyekezwa Kokusebenza Kwezempilo Nokuphepha Esithuthweni.I-Pediatr Neurol. 2019 Julayi; 96: 24-29. i-doi: 10.1016 / j.pediatrneurol. I-PMID: 31053391.

3.Huestis MA, Solimini R, Pichini S, Pacifici R, Carlier J, Busardò FP.Cannabidiol Imiphumela Emibi Nobuthi. I-Curr Neuropharmacol. 2019; 17 (10): 974-989. i-doi: 10.2174 / 1570159X17666190603171901.I-PMID: 31161980.

4. I-Pisanti S, i-Malfitano AM njll i-Cannabidiol: Isimo sobuciko nezinselelo ezintsha zezicelo zokwelapha. I-Pharmacol Ther. 2017 Julayi; 175: 133-150. i-doi: 10.1016 / j.pharmthera.PMID: 28232276.

5. I-Burstein S. Cannabidiol (i-CBD) kanye nama-analogs ayo: ukubuyekezwa kwemiphumela yabo ekuvukeleni.Bioorg Med Chem. 2015 Ephreli 1; 23 (7): 1377-85. i-doi: 10.1016 / j.bmc.2015.01.059. I-PMID: 25703248.

 

Imibhalo Ethrendayo